Yao Gaolei, Huang Yuan, Ping Junjiao, Han Yixuan, Lu Liming, Liu Xinxia, Lu Huipeng
Clinical Research and Big Data Laboratory, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.
Department of Psychiatry, The Third People's Hospital of Zhongshan, Zhongshan, China.
Front Psychiatry. 2025 Jul 11;16:1617068. doi: 10.3389/fpsyt.2025.1617068. eCollection 2025.
To objectively and accurately evaluate the clinical efficacy of transcranial direct current stimulation (tDCS) for schizophrenia, we conducted this systematic review and exploratory meta-analysis (PROSPERO: CRD420251002632).
Firstly, randomized controlled trials (RCTs) related to the adjunctive use of tDCS for schizophrenia were searched on PubMed, Embase and Web of Science databases according to search strategies developed in advance. Secondly, the eligible articles were screened according to the inclusion and exclusion criteria. Finally, the data were extracted and a complete meta-analysis was performed. Meanwhile, we also completed publication bias analysis and sensitivity analysis. Statistical analysis was conducted using RevMan software (version 5.4).
We ultimately included 11 eligible RCTs. The results of the exploratory meta-analysis indicated that the adjunctive use of tDCS seems to be able to enhance the cognitive function of patients (the Paced Auditory Serial Addition Task: standardized mean deviation () = 3.57, 95% confidence interval () (2.60, 4.54), < 0.00001). Subgroup analyses showed that the adjunctive use of tDCS at 15 sessions (Clinical Global Impression-Schizophrenia scale: = -0.56, 95% (-0.87, -0.25), =0.0004) or twice daily (Clinical Global Impression-Schizophrenia scale: = -0.85, 95% (-1.67, -0.03), =0.04) also decreased the disease severity.
This exploratory meta-analysis revealed that tDCS in the treatment of schizophrenia appears capable of improving cognitive function and effectively reducing the severity of the disease. What's more, tDCS has great development potential in schizophrenia, and it may be written into the guidelines for non-drug treatment of schizophrenia in the future. As a matter of fact, this exploratory study points out the direction for future scientific research and clinical practice.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251002632.
为了客观、准确地评估经颅直流电刺激(tDCS)治疗精神分裂症的临床疗效,我们进行了这项系统评价和探索性荟萃分析(国际前瞻性系统评价注册库编号:CRD420251002632)。
首先,根据预先制定的检索策略,在PubMed、Embase和Web of Science数据库中检索与tDCS辅助治疗精神分裂症相关的随机对照试验(RCT)。其次,根据纳入和排除标准筛选符合条件的文章。最后,提取数据并进行完整的荟萃分析。同时,我们还完成了发表偏倚分析和敏感性分析。使用RevMan软件(5.4版)进行统计分析。
我们最终纳入了11项符合条件的RCT。探索性荟萃分析结果表明,tDCS辅助治疗似乎能够增强患者的认知功能(听觉连续加法任务:标准化均数差(SMD)=3.57,95%置信区间(CI)(2.60,4.54),P<0.00001)。亚组分析显示,15次疗程的tDCS辅助治疗(临床总体印象-精神分裂症量表:SMD=-0.56,95%CI(-0.87,-0.25))或每日两次的tDCS辅助治疗(临床总体印象-精神分裂症量表:SMD=-0.85,95%CI(-1.67,-0.03))也降低了疾病严重程度。
这项探索性荟萃分析表明,tDCS治疗精神分裂症似乎能够改善认知功能并有效降低疾病严重程度。此外,tDCS在精神分裂症治疗方面具有巨大的发展潜力,未来可能会被写入精神分裂症非药物治疗指南。事实上,这项探索性研究为未来的科学研究和临床实践指明了方向。